Trials / Completed
CompletedNCT02722590
A Study of Fycompa (Perampanel) in Korean Participants
Post-Marketing Surveillance of Fycompa in Korean Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,692 (actual)
- Sponsor
- Eisai Korea Inc. · Industry
- Sex
- All
- Age
- 4 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this post-marketing surveillance is to observe the following items regarding the safety profile of Fycompa (Perampanel) film-coated tablets and oral suspension in normal clinical practice setting: serious adverse event/adverse drug reaction profile, unexpected adverse event/adverse drug reaction profile, already known adverse drug reaction profile, non-serious adverse event profile and other information related to the product's safety and effectiveness.
Conditions
Timeline
- Start date
- 2016-07-01
- Primary completion
- 2021-06-30
- Completion
- 2021-06-30
- First posted
- 2016-03-30
- Last updated
- 2021-08-09
Locations
9 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02722590. Inclusion in this directory is not an endorsement.